ÂÜÀòÂÒÂ×

Mr. Butera brings more than 30 years of diverse clinical and operations experience to CuraSen, ranging from CROs and large pharma to start-up companies. Before joining CuraSen, Mr. Butera was vice president of clinical operations at Attenua, where he ran the bradanicline program in chronic cough through Phase 2. Previously, he was vice president, clinical operations at Afferent, where he directed clinical operations for programs in chronic pain and cough, until the company’s $1.25 billion acquisition by Merck & Co. in 2016. Earlier, Mr. Butera spent ten years at Pain Therapeutics serving as director and vice president, clinical operations. In this role, he managed clinical development programs for chronic pain compounds in both early and late stage development.

Mr. Butera has a bachelor’s of science degree from Saint Joseph’s University.